Search Options Stock News and Analysis from Schaeffer's

4 Struggling Stocks With “Harmless” Pullbacks

https://www.schaeffersresearch.com/content/bgs/2025/11/18/4-struggling-stocks-with-harmless-pullbacks

11/18/2025 11:05 AM

Subscribers to Chart of the Week received this commentary on Sunday, November 16. Animals, like stocks, have a “story” in their genes. John Maynard Keynes called them animal spirits for a r...

Biotech Stock for Options Bears to Target Right Now

https://www.schaeffersresearch.com/content/analysis/2025/06/11/biotech-stock-for-options-bears-to-target-right-now

6/11/2025 2:41 PM

Biotech stock Crispr Therapeutics Inc's (NASDAQ:CRSP) June rally appears to be coming to an end. The shares are looking to snap a seven-day win streak, down 0.6% at $42.69 at last glance. Plus, after...

3 Gene Therapy Stocks to Watch Amid Industry Turmoil

https://www.schaeffersresearch.com/content/news/2025/03/18/3-gene-therapy-stocks-to-watch-amid-industry-turmoil

3/18/2025 3:21 PM

Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06. The security is pacing for its worst single-day percentage loss since Oc...

Bullish Trendline Has Never Failed Crispr Therapeutics Stock

https://www.schaeffersresearch.com/content/analysis/2024/04/17/bullish-trendline-has-never-failed-crispr-therapeutics-stock

4/17/2024 12:58 PM

Crispr Therapeutics AG (NASDAQ:CRSP) is 2.8% lower at $56.35 this afternoon, continuing a pullback from a Feb. 22, more than two-year high of $91.10. Over the last month, CRSP has erased 20.8% and now...

Crispr Therapeutics Stock Sinks Despite FDA Approval

https://www.schaeffersresearch.com/content/options/2023/12/11/crispr-therapeutics-stock-sinks-despite-fda-approval

12/11/2023 3:31 PM

Crispr Therapeutics AG ( NASDAQ:CRSP) stock is down 7.2% to trade at $59.89 at last check, despite its gene therapy treatment for sickle cell disease in partnership with Vertex (VRTX) last week receiv...

PEOPLE ALSO SEARCH FOR